Corporate Member Update- Bristol Myers Squibb

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

Based on the Phase 3 CheckMate-9DW trial, Opdivo plus Yervoy demonstrated a statistically significant overall survival benefit compared to investigator’s choice of lenvatinib or sorafenib1

In the trial, 38% of patients were still alive at 3 years with this dual immunotherapy vs. 24% with the comparator arm1

To see the full press release, please click here.